In COVID-19, patients were shown to enter a hypercoagulable state with a higher rate of heparin-binding proteins, resulting in an elevated rate of thrombotic complications despite treatment with low-dose heparin for deep-vein thrombosis (DVT) prophylaxis [28,29,30]. The gene discussed is AZU1; the disease is deep vein thrombosis.